MCID: PSR016
MIFTS: 37

Psoriatic Juvenile Idiopathic Arthritis

Categories: Bone diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Psoriatic Juvenile Idiopathic Arthritis

MalaCards integrated aliases for Psoriatic Juvenile Idiopathic Arthritis:

Name: Psoriatic Juvenile Idiopathic Arthritis 20 70
Psoriasis-Related Juvenile Idiopathic Arthritis 20 58 17
Juvenile Psoriatic Arthritis 20 58 70
Psoriasis-Related Jia 20 58
Juvenile Arthritis 70

Characteristics:

Orphanet epidemiological data:

58
psoriasis-related juvenile idiopathic arthritis
Age of onset: Childhood; Age of death: normal life expectancy;

Classifications:

Orphanet: 58  
Rare respiratory diseases
Rare systemic and rhumatological diseases


External Ids:

ICD10 via Orphanet 33 L40.5+ M09.0*
UMLS via Orphanet 71 C0409672
Orphanet 58 ORPHA85436
UMLS 70 C3495559 C3714758 C3890176

Summaries for Psoriatic Juvenile Idiopathic Arthritis

GARD : 20 Psoriatic juvenile idiopathic arthritis is a subtype of juvenile idiopathic arthritis that is characterized by both arthritis and psoriasis. Other signs and symptoms may include dactylitis (inflammation and swelling of an entire finger or toe); nail pitting or splitting; and eye problems. Although the underlying cause of psoriatic juvenile idiopathic arthritis is currently unknown (idiopathic), it is thought to occur due to a combination of genetic and environmental factors. It is very rare for more than one member of a family to have juvenile arthritis; however, research suggests that having a family member with juvenile arthritis or any autoimmune disease may increase the risk of having juvenile arthritis, in general. Treatment usually involves different types of medications to help manage symptoms and/or physical therapy.

MalaCards based summary : Psoriatic Juvenile Idiopathic Arthritis, also known as psoriasis-related juvenile idiopathic arthritis, is related to exanthem and hereditary periodic fever syndrome. An important gene associated with Psoriatic Juvenile Idiopathic Arthritis is MEFV (MEFV Innate Immuity Regulator, Pyrin), and among its related pathways/superpathways are Innate Immune System and NOD-like receptor signaling pathway. The drugs Liver Extracts and Adalimumab have been mentioned in the context of this disorder. Affiliated tissues include eye and liver, and related phenotypes are abnormality of tumor necrosis factor secretion and arthralgia

Related Diseases for Psoriatic Juvenile Idiopathic Arthritis

Diseases related to Psoriatic Juvenile Idiopathic Arthritis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 73)
# Related Disease Score Top Affiliating Genes
1 exanthem 30.1 NLRP3 MEFV
2 hereditary periodic fever syndrome 30.0 NLRP3 MEFV
3 arthritis 29.2 PSTPIP1 NOD2 NLRP3 MEFV
4 familial mediterranean fever 28.8 PSTPIP1 NOD2 NLRP3 MEFV
5 inflammatory bowel disease 28.8 PSTPIP1 NOD2 NLRP3 MEFV
6 pustulosis of palm and sole 10.4
7 psoriasis 10.4
8 juvenile rheumatoid arthritis 10.4
9 psoriatic arthritis 10.2
10 spondyloarthropathy 1 10.2
11 juvenile arthritis 10.2
12 inflammatory spondylopathy 10.2
13 spondylitis 10.2
14 juvenile ankylosing spondylitis 10.1
15 arthropathy 10.1
16 plica syndrome 10.1
17 uveitis 10.1
18 synovitis 10.1
19 tenosynovitis 10.1
20 erysipeloid 10.0 PSTPIP1 MEFV
21 celiac disease 1 10.0
22 osteoid osteoma 10.0
23 branchiootic syndrome 1 10.0
24 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.0
25 ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus 10.0
26 proteinuria, chronic benign 10.0
27 autosomal recessive disease 10.0
28 sensorineural hearing loss 10.0
29 renal hypertension 10.0
30 brucellosis 10.0
31 glomerulonephritis 10.0
32 inner ear disease 10.0
33 acute kidney failure 10.0
34 skin disease 10.0
35 iridocyclitis 10.0
36 autoimmune inner ear disease 10.0
37 polyarticular juvenile idiopathic arthritis 10.0
38 neutrophilic dermatosis, acute febrile 10.0 PSTPIP1 MEFV
39 wells syndrome 10.0 NLRP3 MEFV
40 familial cold autoinflammatory syndrome 1 9.9 NLRP3 MEFV
41 cervical adenitis 9.9 NLRP3 MEFV
42 familial cold autoinflammatory syndrome 2 9.9 NLRP3 MEFV
43 chronic meningitis 9.9 NLRP3 MEFV
44 pharyngitis 9.9 NLRP3 MEFV
45 adult-onset still's disease 9.9 NLRP3 MEFV
46 chondrocalcinosis 9.9 NLRP3 MEFV
47 peroxisomal disease 9.9 NLRP3 MEFV
48 aphthous stomatitis 9.9 NLRP3 MEFV
49 stomatitis 9.9 NLRP3 MEFV
50 proteasome-associated autoinflammatory syndrome 1 9.8 NLRP3 MEFV

Graphical network of the top 20 diseases related to Psoriatic Juvenile Idiopathic Arthritis:



Diseases related to Psoriatic Juvenile Idiopathic Arthritis

Symptoms & Phenotypes for Psoriatic Juvenile Idiopathic Arthritis

Human phenotypes related to Psoriatic Juvenile Idiopathic Arthritis:

58 31 (show all 29)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 abnormality of tumor necrosis factor secretion 58 31 hallmark (90%) Very frequent (99-80%) HP:0011118
2 arthralgia 58 31 frequent (33%) Frequent (79-30%) HP:0002829
3 pruritus 58 31 frequent (33%) Frequent (79-30%) HP:0000989
4 nail pits 58 31 frequent (33%) Frequent (79-30%) HP:0001803
5 psoriasiform dermatitis 58 31 frequent (33%) Frequent (79-30%) HP:0003765
6 enthesitis 58 31 frequent (33%) Frequent (79-30%) HP:0100686
7 antinuclear antibody positivity 58 31 frequent (33%) Frequent (79-30%) HP:0003493
8 polyarticular arthritis 58 31 frequent (33%) Frequent (79-30%) HP:0005764
9 finger dactylitis 58 31 frequent (33%) Frequent (79-30%) HP:0031090
10 toe dactylitis 58 31 frequent (33%) Frequent (79-30%) HP:0031091
11 oligoarthritis 58 31 frequent (33%) Frequent (79-30%) HP:0040313
12 reduced visual acuity 58 31 occasional (7.5%) Occasional (29-5%) HP:0007663
13 abnormality of the wrist 58 31 occasional (7.5%) Occasional (29-5%) HP:0003019
14 abnormality of the knee 58 31 occasional (7.5%) Occasional (29-5%) HP:0002815
15 malar rash 58 31 occasional (7.5%) Occasional (29-5%) HP:0025300
16 generalized morning stiffness 58 31 occasional (7.5%) Occasional (29-5%) HP:0005197
17 psoriasiform lesion 58 31 occasional (7.5%) Occasional (29-5%) HP:0025526
18 abnormal shoulder morphology 31 occasional (7.5%) HP:0003043
19 onycholysis 58 31 very rare (1%) Very rare (<4-1%) HP:0001806
20 abnormality of the temporomandibular joint 58 31 very rare (1%) Very rare (<4-1%) HP:0010754
21 iridocyclitis 58 31 very rare (1%) Very rare (<4-1%) HP:0001094
22 sacroiliac arthritis 58 31 very rare (1%) Very rare (<4-1%) HP:0012317
23 iritis 58 31 very rare (1%) Very rare (<4-1%) HP:0001101
24 autoimmunity 58 Frequent (79-30%)
25 uveitis 58 Occasional (29-5%)
26 skin rash 58 Occasional (29-5%)
27 limitation of joint mobility 58 Occasional (29-5%)
28 abnormality of the shoulder 58 Occasional (29-5%)
29 anterior uveitis 58 Occasional (29-5%)

Drugs & Therapeutics for Psoriatic Juvenile Idiopathic Arthritis

Drugs for Psoriatic Juvenile Idiopathic Arthritis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 27)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Liver Extracts Phase 4
2
Adalimumab Approved, Experimental Phase 3 331731-18-1 16219006
3
Ixekizumab Approved, Investigational Phase 3 1143503-69-8
4
Apremilast Approved, Investigational Phase 3 608141-41-9 11561674
5
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
6
Levoleucovorin Approved, Investigational Phase 3 68538-85-2 149436
7
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
8 Anti-Inflammatory Agents Phase 3
9 Analgesics, Non-Narcotic Phase 3
10 Analgesics Phase 3
11 Anti-Inflammatory Agents, Non-Steroidal Phase 3
12 Vitamin B9 Phase 3
13 Folic Acid Antagonists Phase 3
14 Antibodies Phase 3
15 Immunoglobulins Phase 3
16 Antirheumatic Agents Phase 3
17 Immunosuppressive Agents Phase 3
18 Immunologic Factors Phase 3
19 Vitamin B Complex Phase 3
20 Dermatologic Agents Phase 3
21 Folate Phase 3
22 Antimetabolites Phase 3
23 Mitogens Phase 3
24 Hormones Phase 3
25
Acetaminophen Approved 103-90-2 1983
26 Antibodies, Antinuclear
27 Vaccines

Interventional clinical trials:

(show all 16)
# Name Status NCT ID Phase Drugs
1 A Phase IV Study to Evaluate Decreased Dose Frequency in Patients With Systemic Juvenile Arthritis (SJIA) Who Experience Laboratory Abnormalities During Treatment With Tocilizumab Completed NCT01734382 Phase 4 Tocilizumab
2 A Three-part Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Secukinumab Treatment in Juvenile Idiopathic Arthritis Subtypes of Psoriatic and Enthesitis-related Arthritis Completed NCT03031782 Phase 3 AIN457
3 An Extension Study of Subcutaneous Secukinumab to Evaluate the Long-term Efficacy, Safety and Tolerability up to 4 Years in Patients With Juvenile Idiopathic Arthritis Subtypes of Juvenile Psoriatic Arthritis and Enthesitis Related Arthritis Recruiting NCT03769168 Phase 3 AIN457
4 Multicenter, Open-label, Efficacy, Safety, Tolerability, and Pharmacokinetic Study of Subcutaneous Ixekizumab With Adalimumab Reference Arm, in Children With Juvenile Idiopathic Arthritis Subtypes of Enthesitis-related Arthritis (Including Juvenile-Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis Not yet recruiting NCT04527380 Phase 3 Ixekizumab;Adalimumab
5 A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Apremilast in Children From 5 to Less Than 18 Years of Age With Active Juvenile Psoriatic Arthritis (PEAPOD) Not yet recruiting NCT04804553 Phase 3 Apremilast;Placebo
6 A Multicenter, Double-Blind, Randomized-Withdrawal Trial of Subcutaneous Golimumab, a Humanized Anti-TNFa Antibody, in Subjects With Active Polyarticular Juvenile Idiopathic Arthritis (JIA) Despite Standard Therapy Terminated NCT01230827 Phase 3 CNTO 148 (Golimumab);Placebo;Methotrexate
7 Prevention of Retarded Growth by Early Treatment With Recombinant Human Growth Factor Genotonorm (Registered) in Children With Systemic Forms of Chronic Juvenile Arthritis Receiving Long-term Corticosteroid Therapy. Extension of the Study Beyond Three Years Terminated NCT00174291 Phase 3 Somatropin
8 The Effect of Vigorous Exercise on Motor Function and Functional Fitness in Juvenile Arthritis Completed NCT00213187 Phase 2
9 Usefulness of Protoarray®Microarray for Identifying Biomarkers in Idiopathic Juvenile Arthritis Antinuclear Antibodies Positive. Unknown status NCT02343770
10 Research Registry for Juvenile Arthritis Unknown status NCT00090571
11 Does Thermal Imaging Correlate With Musculoskeletal Examination in the Identification of Inflamed Joints in Children and Young People With Juvenile Idiopathic Arthritis? A Prospective Diagnostic Accuracy Study Completed NCT04228458
12 Jointstrong Intervention for Juvenile Arthritis Completed NCT01166750
13 Prospective Multi-Center Observational Study to Assess Persistence, Adherence and Changes in Disease Activity in the Children Population of Juvenile Arthritis Patients Treated With Adalimumab (HUMIRA) in the Routine Clinical Settings in the Russian Federation (PETITE) Completed NCT03383263
14 C.O.R.P.U.S. : Observational Cohort of Active Rheumatoid Arthritis, Spondylarthropathy and Idiopathic Juvenile Arthritis in France Completed NCT02886689 TNF-alpha antagonist and other biotherapy
15 Human Papilloma Virus Vaccination and Chronic Inflammatory Rheumatic Disease. A Cross-sectional Study of Vaccinal Coverage, Barriers and Motivations. Recruiting NCT04180228
16 Massage Therapy for Children With Juvenile Idiopathic Arthritis Experiencing Pain: a Pilot Randomized Controlled Trial Terminated NCT02218580

Search NIH Clinical Center for Psoriatic Juvenile Idiopathic Arthritis

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Aurothioglucose
Diclofenac
Diclofenac Potassium
Diclofenac Sodium
Etanercept
Ibuprofen
Methotrexate
Methotrexate Sodium
Naproxen
Naproxen sodium
oxaprozin
solufenum
Sulfasalazine
tocilizumab
Tolmetin
Tolmetin Sodium

Genetic Tests for Psoriatic Juvenile Idiopathic Arthritis

Anatomical Context for Psoriatic Juvenile Idiopathic Arthritis

MalaCards organs/tissues related to Psoriatic Juvenile Idiopathic Arthritis:

40
Eye, Liver

Publications for Psoriatic Juvenile Idiopathic Arthritis

Articles related to Psoriatic Juvenile Idiopathic Arthritis:

# Title Authors PMID Year
1
Rapid Resolution of Erosive Psoriatic Juvenile Idiopathic Arthritis With Anti-Tumor Necrosis Factor Therapy. 61
33136694 2020
2
Juvenile idiopathic arthritis in a center in the Western Anatolia region in Turkey. 61
32684761 2020
3
Enthesitis as a component of dactylitis in psoriatic juvenile idiopathic arthritis: histology of an established clinical entity. 61
25774101 2015
4
Psoriatic juvenile idiopathic arthritis associated with uveitis: a case report. 61
24191219 2013
5
Psoriatic juvenile idiopathic arthritis: a tale of two subgroups. 61
21709556 2011
6
Autoinflammatory genes and susceptibility to psoriatic juvenile idiopathic arthritis. 61
18576390 2008

Variations for Psoriatic Juvenile Idiopathic Arthritis

Expression for Psoriatic Juvenile Idiopathic Arthritis

Search GEO for disease gene expression data for Psoriatic Juvenile Idiopathic Arthritis.

Pathways for Psoriatic Juvenile Idiopathic Arthritis

GO Terms for Psoriatic Juvenile Idiopathic Arthritis

Cellular components related to Psoriatic Juvenile Idiopathic Arthritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 lamellipodium GO:0030027 8.62 PSTPIP1 MEFV

Biological processes related to Psoriatic Juvenile Idiopathic Arthritis according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 9.56 PSTPIP1 NOD2 NLRP3 MEFV
2 inflammatory response GO:0006954 9.54 PSTPIP1 NLRP3 MEFV
3 cellular response to lipopolysaccharide GO:0071222 9.52 NOD2 NLRP3
4 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.51 NOD2 NLRP3
5 defense response GO:0006952 9.49 NOD2 NLRP3
6 negative regulation of inflammatory response GO:0050728 9.48 NLRP3 MEFV
7 negative regulation of NF-kappaB transcription factor activity GO:0032088 9.46 NOD2 NLRP3
8 innate immune response GO:0045087 9.46 PSTPIP1 NOD2 NLRP3 MEFV
9 positive regulation of interleukin-1 beta production GO:0032731 9.43 NOD2 NLRP3
10 negative regulation of interleukin-1 beta production GO:0032691 9.4 NLRP3 MEFV
11 negative regulation of interleukin-12 production GO:0032695 9.32 NOD2 MEFV
12 positive regulation of type 2 immune response GO:0002830 8.96 NOD2 NLRP3
13 detection of biotic stimulus GO:0009595 8.62 NOD2 NLRP3

Molecular functions related to Psoriatic Juvenile Idiopathic Arthritis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 peptidoglycan binding GO:0042834 8.62 NOD2 NLRP3

Sources for Psoriatic Juvenile Idiopathic Arthritis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....